{"nctId":"NCT02518945","briefTitle":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","startDateStruct":{"date":"2015-08","type":"ACTUAL"},"conditions":["Type 1 Diabetes Mellitus"],"count":26,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Insulin","Drug: Liraglutide","Drug: Dapagliflozin placebo"]},{"label":"Active drugs","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dapagliflozin","Drug: Insulin","Drug: Liraglutide"]}],"interventions":[{"name":"Dapagliflozin","otherNames":["Farxiga"]},{"name":"Insulin","otherNames":["Lantus, Levemir, Toujjeo, Humalog , Novolog, Apidra"]},{"name":"Liraglutide","otherNames":["Victoza"]},{"name":"Dapagliflozin placebo","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with type 1 diabetes mellitus: Fasting c-peptide \\< 0.1nmol/l on insulin therapy for more than 12 months with or without history of diabetic ketoacidosis and treatment with liraglutide at maximal tolerated doses for at least 6 months prior to start of the study.\n* Willing to use a continuous glucose monitoring device (CGM) and regularly measuring their blood sugars four times daily\n* HbA1c of less than or equal to 11%.\n* Well versed with carbohydrate counting\n* Age 18-75 years\n\nExclusion Criteria:\n\n* Type 1 diabetes for less than 12 months.\n* Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks\n* Hepatic disease (transaminase \\> 3 times normal) or cirrhosis\n* ESRD on hemodialysis; and or e-GFR less than 30 ml/min/1.73m2\n* HIV or Hepatitis C positive status\n* Participation in any other concurrent clinical trial\n* Any other life-threatening, non-cardiac disease\n* Use of an investigational agent or therapeutic regimen within 30 days of study\n* History of pancreatitis\n* Pregnancy\n* Inability to give informed consent\n* History of gastroparesis\n* History of medullary thyroid carcinoma or MEN 2 syndrome\n* Family history of MEN 2, Family history of medullary thyroid cancer, or familial medullary thyroid cancer\n* Women of childbearing potential who are not using adequate contraception\n* Women who are pregnant\n* History of serious hypersensitivity reaction to these agents.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.","description":"T1D. Conservatively estimating a difference in mean HbA1c (the primary end point) of 0.5% before and after the treatment, and a sample size of 30 (2:1 drug to placebo ratio) should provide adequate power (.8) to detect a significant difference (.05) provided the standard deviation of the residuals in not greater than 0.4%. The sample size includes an additional 20% to account for the potential dropout.\n\nChanges in these end points were calculated by averaging the differences in weekly average values from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.2"},{"groupId":"OG001","value":"-0.66","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Change in Time Spent at Normal Glucose Concentrations Between 70-160mg/dl","description":"Comparison of the change in time spent at normal glucose concentrations between 70-180mg/dl after treatment with 12 weeks of dapagliflozin in addition to liraglutide and insulin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"1.0"},{"groupId":"OG001","value":"10","spread":"4"}]}]}]},{"type":"SECONDARY","title":"Change in 24-hour Urine Glucose Excretion.","description":"Comparison of change in 24-hour urine glucose excretion after 12 weeks of treatment of dapagliflozin in addition to liraglutide and insulin compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.1"},{"groupId":"OG001","value":"66.9","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Change in Total Daily Insulin Requirements","description":"Comparison of the change from baseline in total daily insulin requirements in units per kilogram after treatment 12 weeks of dapagliflozin or placebo in addition to liraglutide and insulin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.4"},{"groupId":"OG001","value":"-3.5","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Comparison of change from baseline in Body weight after 12 weeks treatment with dapagliflozin or placebo in addition to liraglutide and insulin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.5"},{"groupId":"OG001","value":"-1.9","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure Before and After Treatment","description":"Comparison of Systolic blood pressure in mm Hg before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"3"},{"groupId":"OG001","value":"-12","spread":"4"}]}]}]},{"type":"SECONDARY","title":"Change in Blood Ketone Bodies","description":"change from baseline in blood ketone bodies (measured as beta-hydroxybutyrates) after 12 weeks treatment with dapagliflozin or placebo in addition to liraglutide and insulin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.06"},{"groupId":"OG001","value":"0.20","spread":"0.09"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":[]}}}